90332-66-4

Basic information

• Product Name: XYLOTAXOL, 7-(RG)
• Synonyms: XYLOTAXOL, 7-(RG);(alphaR,betaS)-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-4-(D-xylopyranosyloxy)-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester;Taxol-7-xyloside;XYLOTAXOL, 7-(P)
• CAS NO: 90332-66-4
• Molecular Formula: C52H59NO18
• Molecular Weight: 986.03636
• Product Categories: Plant extract;Plant extracts;Herb extract
• Mol File: 90332-66-4.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 1062.337 °C at 760 mmHg
• Flash Point: 596.28 °C
• Appearance: /
• Density: 1.45
• PKA: 11.90±0.20(Predicted)
• CAS DataBase Reference: XYLOTAXOL, 7-(RG)(CAS DataBase Reference)
• NIST Chemistry Reference: XYLOTAXOL, 7-(RG)(90332-66-4)
• EPA Substance Registry System: XYLOTAXOL, 7-(RG)(90332-66-4)

Safety Data

• Hazardous Substances Data: 90332-66-4(Hazardous Substances Data)

Usage

Description

XYLOTAXOL, 7-(RG) is a chemical compound that is utilized as a precursor in the semisynthesis of Paclitaxel, an effective anticancer drug. It is produced by the bacterial strain Moraxella species, which removes the xylosyl group from xylosyltaxanes, making them available for further processing. XYLOTAXOL, 7-(RG) plays a crucial role in the production of a life-saving medication for cancer patients.

Uses

Used in Pharmaceutical Industry:
XYLOTAXOL, 7-(RG) is used as a precursor compound for the semisynthesis of Paclitaxel (P132500), an anticancer treatment. It serves as a vital intermediate in the production process, enabling the creation of a medication that has been proven effective against various types of cancer.
The use of XYLOTAXOL, 7-(RG) in the pharmaceutical industry is primarily for the following reasons:
1. It allows for the efficient production of Paclitaxel, a drug that has been widely used in the treatment of different types of cancer, including ovarian, breast, and lung cancer.
2. The semisynthesis process using XYLOTAXOL, 7-(RG) as a precursor ensures a more sustainable and cost-effective method of producing Paclitaxel, making it more accessible to patients in need.
3. The involvement of the bacterial strain Moraxella species in the production of XYLOTAXOL, 7-(RG) highlights the potential of biotechnological approaches in the development of pharmaceutical compounds, opening up new avenues for research and innovation in the industry.